Divalproex Sodium Tablet, Delayed Release
NDC Package 0615-8586-39
Package Information
Divalproex Sodium tablets is divalproex sodium delayed-release tablets should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)].Divalproex sodium delayed-release tablets are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].Divalproex sodium delayed-release tablets are contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)].Divalproex sodium delayed-release tablets are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].For use in prophylaxis of migraine headaches: Divalproex sodium delayed-release tablets are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2, 5.3, 5.4) and Use in Specific Populations (8.1)]. This formulation utilizes a tablet, delayed release delivery system. Marketed by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, this product is identified by NDC 0615-8586 and is authorized under FDA application ANDA078853.
Identification & Billing
- RxCUI: 1099625 - divalproex sodium 125 MG Delayed Release Oral Tablet
- RxCUI: 1099678 - divalproex sodium 250 MG Delayed Release Oral Tablet
- RxCUI: 1099870 - divalproex sodium 500 MG Delayed Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0615 - Ncs Healthcare Of Ky, Llc Dba Vangard Labs
- 0615-8586 - Divalproex Sodium
- 0615-8586-39 - 30 TABLET, DELAYED RELEASE in 1 BLISTER PACK
- 0615-8586 - Divalproex Sodium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0615-8586-39 identifies a specific commercial package of 30 tablet, delayed release in 1 blister pack of Divalproex Sodium, a human prescription drug labeled by Ncs Healthcare Of Ky, Llc Dba Vangard Labs. This tablet, delayed release is formulated for oral use and contains divalproex sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ncs Healthcare Of Ky, Llc Dba Vangard Labs on June 26, 2024. The current certification is valid through December 31, 2027.
How is this Ncs Healthcare Of Ky, Llc Dba Vangard Labs product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00615858639. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.